title: [How phase III therapeutic trials in multiple sclerosis should be evaluated: advances and challenges].
authors.affiliation: UCSF/Mt Zion Multiple Sclerosis Center, San Francisco, CA 94115, USA.
authors.forename: E
authors.initials: E
authors.lastname: Waubant
authors.forename: D
authors.initials: D
authors.lastname: Goodkin
mesh_terms: D001284:Atrophy / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000401:mortality / Q000628:therapy*; D013116:Spinal Cord / Q000473:pathology; D015996:Survival Rate; D013997:Time Factors
vernacular_title: Comment évaluer les résultats d'essais thérapeutiques de phase III dans la sclérose en plaques: progrès et défis.